Patricia de Groot on Muck Rack

Patricia de Groot

Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Patricia

Contact Patricia, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

First Report of Response to Tarlatamab in a Patient With Histologic-Transformed SCLC From ALK-Rearranged NSCLC: Case Report

|
By Lauren A Byers, Kaiwen WANG, Patricia de Groot, Mitchell A. Parma
| jtocrr.org
Keywords Tarlatamab Small cell transformation ALK Lorlatinib Case report Introduction ALK rearrangement accounts for approximately 4% of targetable oncogenic driver in NSCLC cases.1 Multiple generations of ALK inhibitors have been developed with alectinib, brigatinib, and lorlatinib found to have favorable survival outcomes compared with the earlier generation ALK tyrosine kinase inhibitors (TKIs), such as crizotinib and ceritinib.2–4 Progression-free survival (PFS) with alectinib was...
Open in Who Shared Issue with article?
See all 1 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified